TPST Tempest Therapeutics, Inc.

Nasdaq tempesttx.com


$ 12.15 $ 0.30 (2.6 %)    

Tuesday, 14-Oct-2025 19:40:23 EDT
QQQ $ 598.50 $ -4.01 (-0.67 %)
DIA $ 463.08 $ 2.03 (0.44 %)
SPY $ 662.74 $ -0.81 (-0.12 %)
TLT $ 90.69 $ 0.29 (0.32 %)
GLD $ 382.95 $ 2.70 (0.71 %)
$ 11.83
$ 11.40
$ 11.00 x 3
$ 12.26 x 1
$ 10.88 - $ 12.09
$ 5.35 - $ 20.67
89,240
na
52.53M
$ 2.68
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-11-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 03-27-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 03-19-2024 12-31-2023 10-K
8 11-08-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-10-2023 03-31-2023 10-Q
11 03-22-2023 12-31-2022 10-K
12 11-08-2022 09-30-2022 10-Q
13 08-15-2022 06-30-2022 10-Q
14 05-13-2022 03-31-2022 10-Q
15 03-29-2022 12-31-2021 10-K
16 11-10-2021 09-30-2021 10-Q
17 08-12-2021 06-30-2021 10-Q
18 05-13-2021 03-31-2021 10-Q
19 03-29-2021 12-31-2020 10-K
20 11-09-2020 09-30-2020 10-Q
21 08-10-2020 06-30-2020 10-Q
22 05-08-2020 03-31-2020 10-Q
23 03-11-2020 12-31-2019 10-K
24 11-13-2019 09-30-2019 10-Q
25 08-12-2019 06-30-2019 10-Q
26 05-15-2019 03-31-2019 10-Q
27 04-01-2019 12-31-2018 10-K
28 11-09-2018 09-30-2018 10-Q
29 08-09-2018 06-30-2018 10-Q
30 05-03-2018 03-31-2018 10-Q
31 03-15-2018 12-31-2017 10-K
32 11-02-2017 09-30-2017 10-Q
33 08-03-2017 06-30-2017 10-Q
34 05-09-2017 03-31-2017 10-Q
35 03-02-2017 12-31-2016 10-K
36 11-03-2016 09-30-2016 10-Q
37 08-04-2016 06-30-2016 10-Q
38 05-05-2016 03-31-2016 10-Q
39 02-26-2016 12-31-2015 10-K
40 11-05-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 tempest-therapeutics-q2-eps-207-beats-323-estimate

Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(2.07) per share which beat the analyst consensus estimate of ...

 tempest-announces-it-has-received-orphan-drug-designation-from-european-medicines-agency-for-its-amezalpat-for-treatment-of-patients-with-hepatocellular-carcinoma

EMA Orphan Drug Designation (ODD) builds on U.S. Food & Drug Administration (FDA) ODD and Fast Track Designation, underscor...

 tempest-therapeutics-q1-eps-316-beats-371-estimate

Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(3.16) per share which beat the analyst consensus estimate of ...

 tempest-weighs-ma-analyst-sees-a-broken-story-despite-phase-2-liver-cancer-study-success

Tempest Therapeutics hires MTS Health to explore M&A and partnerships after Roche shows limited interest in its liver cance...

 correction--scotiabank-downgrades-tempest-therapeutics-to-sector-perform-raises-price-target-to-9-previous-target-changed

Correction: Scotiabank analyst George Farmer downgrades Tempest Therapeutics (NASDAQ:TPST) from Sector Outperform to Sector Per...

 hc-wainwright--co-downgrades-tempest-therapeutics-to-neutral-maintains-price-target-to-16

HC Wainwright & Co. analyst Joseph Pantginis downgrades Tempest Therapeutics (NASDAQ:TPST) from Buy to Neutral and maint...

 tempest-therapeutics-plans-to-explore-strategic-alternatives-to-advance-promising-clinical-stage-programs-and-maximize-stockholder-value

Amezalpat (TPST-1120) is Phase 3-ready: completed FDA and EMA interactions for first-line pivotal study in hepatocellular carci...

 scotiabank-maintains-sector-outperform-on-tempest-therapeutics-lowers-price-target-to-7

Scotiabank analyst George Farmer maintains Tempest Therapeutics (NASDAQ:TPST) with a Sector Outperform and lowers the price ...

 hc-wainwright--co-maintains-buy-on-tempest-therapeutics-lowers-price-target-to-16

HC Wainwright & Co. analyst Joseph Pantginis maintains Tempest Therapeutics (NASDAQ:TPST) with a Buy and lowers the pric...

 tempest-therapeutics-fy-2024-gaap-eps-150-misses-138-estimate

Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(1.50) per share which missed the analyst consensus estimate o...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION